Undesired reactions recorded during the research and during the post-registration period are classified by frequency (very frequent (> 1/10), frequent (≥1 / 100, <1/10), infrequent (≥1 / 1000, <1/100 ), rare (≥1 / 10000, <1/1000).
From the nervous system
Often: headache.
Rarely: dizziness, paresthesia.
From the side of the organ of vision
Very often: burning and pain.
Often: superficial punctate keratitis, lacrimation, conjunctivitis, inflammation of the eyelids, itching, eyelid irritation, blurred vision.
Infrequently: iridocyclitis.
Rarely: reddening of the eyes, pain, hyperkeratosis of the eyelids, transient myopia (disappearing after drug discontinuation), corneal edema, decreased intraocular pressure, detachment of the choroidal coat of the eyes after surgical interventions to restore outflow of intraocular fluid.
On the part of the respiratory system, thorax and mediastinum
Rarely: nosebleeds.
From the gastrointestinal tract
Often: nausea, bitter taste in the mouth.
Rarely: pharyngitis, dry mouth.
From the skin and mucous membranes
Rarely: contact dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis.
From the side of the urinary tract
Rarely: urolithiasis.
General disorders and disorders at the site of administration
Often: asthenia, fatigue.
Rarely: allergic reactions - signs and symptoms of local reactions (eyelid) and systemic allergic reactions, including angioedema, urticaria, pruritus, rash, difficulty breathing, less often - bronchospasm.
Children
In children younger than 6 years, the profile of adverse reactions of dorzolamide is comparable to the profile of adverse reactions in adult patients. The most frequent adverse reactions associated with the use of dorsolamide in children younger than 2 years of age were conjunctival injection (5.4%) and discharge from the eyes (3.6%). In children from 2 to 6 years, the most frequent adverse reactions were a burning sensation in the eye (12.1%), conjunctival injection (7.6%), eye pain (3%), inflammation of the eyelids (3%).